The wellbeing-informed shared decisions about oncology management study

Wellbeing-Informed Shared Decisions about Oncology management (WISDOM): a non-randomised feasibility study testing the WISDOM intervention in patients with advanced gastro-intestinal and lung cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12250298

Enrollment

Registered

2025-08-13

Start date

2025-08-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty-informed care in older adults with advanced gastro-intestinal or lung cancer Cancer

Interventions

This feasibility study will begin to evaluate the first protoype of WISDOM*. WISDOM is a complex intervention which has been co-designed with patients, healthcare professionals and academic experts to

re-named in response to stakeholder input) Patients taking part in the study will: 1. Receive a short wellbeing/frailty assessment before their first oncology appointment. 2. Be given clear, easy-to-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Older patients (=65 years) with colorectal, anal, gastro-oesophageal, pancreatic or lung malignancies (any histology) being referred to oncology primarily for consideration for first-line palliative SACT. This would include medically or technically inoperable stage 3/4 disease. 2. Booked for an oncology new patient appointment with an oncologist who is participating in the study

Exclusion criteria

Exclusion criteria: 1. Patients lacking the capacity to consent to participation 2. Unable to complete patient-reported outcome measures (PROMs) with support

Design outcomes

Primary

Measure	Time frame
In line with feasibility aims, the primary outcomes include the following process measures: 1. Participant uptake/recruitment recorded as the proportion of eligible patients approached and subsequently consented within the study period (6-12 months) 2. Retention at follow-up recorded as the proportion of participants consented who complete PFU1/2 (at 2 and 8 weeks post baseline, respectively) 3. Completeness of data captured in questionnaires at each timepoint (baseline, 2 and 8 weeks), recorded as the proportion of participants completing each questionnaire and the proportion of missing responses for item	—

Measure

Time frame

In line with feasibility aims, the primary outcomes include the following process measures: 1. Participant uptake/recruitment recorded as the proportion of eligible patients approached and subsequently consented within the study period (6-12 months) 2. Retention at follow-up recorded as the proportion of participants consented who complete PFU1/2 (at 2 and 8 weeks post baseline, respectively) 3. Completeness of data captured in questionnaires at each timepoint (baseline, 2 and 8 weeks), recorded as the proportion of participants completing each questionnaire and the proportion of missing responses for item

—

Secondary

Measure	Time frame
Short-term change in quality of life will be evaluated at 2 and 8 weeks post-baseline using the following Patient Reported Outcome Measures (PROMs): 1. EuroQol-5 Dimension (EQ5D)-5L 2. EORTC quality-of-life questionnaires (QLQ)-C30 3. EORTC QLQ-ELD14 The SHARED questionnaire will also be completed by patients at 2 weeks post baseline to evaluate the decision-making process.	—

Countries

England, United Kingdom

Contacts

Public ContactJessica Pearce

J.Pearce@leeds.ac.uk+44 (0)113 343 0998

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026